<DOC>
	<DOCNO>NCT01613131</DOCNO>
	<brief_summary>Hormonal treatment perimenopausal woman frequently utilized oral contraceptive pill ( OCPs ) . Because ability suppress ovulation establish cycle control , OCPs become popular option , one FDA approve use menopause . However , use OCPs woman 40 's 50 's carry significant cardiovascular risk . Venous thromboembolism risk 3-6 fold great OCP user , risk myocardial infarction ( MI ) approximately double OCP user age 40 . This occur age background population risk MI begin increase , absolute number case rise substantially . Women additional risk factor cardiovascular disease much great risk MI ( 6-40-fold ) association OCPs . There also large subgroup midlife woman candidate OCP use , smoker migraineurs . Moreover , trend towards low estrogen dose OCPs contain 20 microgram ethinyl estradiol lead detectable decrease thromboembolic risk . Because increased potential risk , appropriate seek alternative OCPs explore low dos hormone relieve perimenopausal symptom occur prior woman 's final menses . Recent evidence indicate hypothalamic-pituitary axis reproductively age woman susceptible suppression sex steroid previously believe . It possible hormone dose low 50 microgram transdermal estradiol ( TDE ) suppress hypothalamic-pituitary axis midlife woman . It also tempt speculate low measurable circulating dos levonorgestrel present woman use Mirena intrauterine system ( IUS ) contribute even independently suppress hypothalamic-pituitary axis , reduce hormonal fluctuation result worsen perimenopausal symptom . The combination low dose TDE plus Mirena may therefore confer superior symptom control well contraceptive effectiveness , far less risk .</brief_summary>
	<brief_title>Mirena Estrogen Control Perimenopause Symptoms Ovulation Suppression</brief_title>
	<detailed_description>The Specific Aims present proposal therefore follow : Aim 1 : To test hypothesis low dose estrogen therapy concert low dos levonorgestrel circulate Mirena use suppress ovulation perimenopausal woman . Aim 2 : To examine ovulation rate symptom control Mirena alone , assess tolerability combine estrogen therapy plus Mirena IUS treatment option symptomatic perimenopausal woman . The propose pilot study design test feasibility tolerability propose regimen : Mirena alone Mirena plus low-dose TDE treating symptom perimenopausal woman provide preliminary data large , comparative effectiveness study optimal symptom control provision long term contraception midlife woman within 5 year final menstrual period .</detailed_description>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Age 4052 History regular menstrual cycle every 2035 day midreproductive life ( 2035 year age ) At least 1 period within past 3 month BMI le 35 kg/m2 Presence least one follow perimenopausal symptom : 1 . Hot flash ( vasomotor symptom ) 2 . Cyclical headache , bloat adverse mood 3 . Selfreported poor quality sleep Age &lt; 40 year Hysterectomy bilateral oophorectomy Cigarette smoking Signs symptoms restless leg syndrome sleep apnea Any chronic renal hepatic disease might interfere excretion gonadotropin sex steroid Moderate/vigorous aerobic exercise &gt; 4 hour per week Inability read/write English Pregnant Women Prisoners Decisionally challenge subject Any medical condition make use Topical estradiol Mirena contraindicate . Sex hormone use within past 30 day History cancer , blood clot blood clot disorder</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>52 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>